Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Current antiplatelet therapy in acute coronary syndrome have a focus on the dual antiplatelet
therapy including aspirin and clopidogrel. However, the patient's drug resistance of aspirin
and clopidogrel is the important cause of poor clinical prognosis. Therefore, recently,
clinical research about the triple antiplatelet therapy including cilostazol is actively
conducted. But, clinical research about triple antiplatelet therapy for acute myocardial
infarction is inadequate situation, and the ideal duration of triple antiplatelet therapy has
been actively discussed. Therefore, we try to evaluate the clinical outcomes of triple
antiplatelet therapy in acute myocardial infarction patients undergoing percutaneous
intervention with drug eluting stent compared with dual antiplatelet therapy and investigate
ideal duration of triple antiplatelet therapy through this research.